Meropenem Venus Pharma 1 g inj./inf. sol. (pwdr.) i.v. vial Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

meropenem venus pharma 1 g inj./inf. sol. (pwdr.) i.v. vial

venus pharma gmbh - meropenem trihydrate 1141 mg - eq. meropenem 1000 mg - powder for solution for injection/infusion - 1 g - meropenem trihydrate 1141 mg - meropenem

Meropenem Venus Pharma 2 g inj./inf. sol. (pwdr.) i.v. vial Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

meropenem venus pharma 2 g inj./inf. sol. (pwdr.) i.v. vial

venus pharma gmbh - meropenem trihydrate 2282 mg - eq. meropenem 2000 mg - powder for solution for injection/infusion - 2 g - meropenem trihydrate 2282 mg - meropenem

DBL™ Meropenem for Injection New Zealand - engelsk - Medsafe (Medicines Safety Authority)

dbl™ meropenem for injection

pfizer new zealand limited - meropenem trihydrate 1140.95mg equivalent to meropenem 1000 mg - powder for injection - 1 g - active: meropenem trihydrate 1140.95mg equivalent to meropenem 1000 mg excipient: nitrogen sodium carbonate - dbl meropenem for injection is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: · community acquired lower respiratory tract infection · hospital acquired lower respiratory tract infection · complicated urinary tract infection · febrile neutropenia · intra-abdominal and gynaecological (polymicrobial) infections · complicated skin and skin structure infections · meningitis · septicaemia

DBL™ Meropenem for Injection New Zealand - engelsk - Medsafe (Medicines Safety Authority)

dbl™ meropenem for injection

pfizer new zealand limited - meropenem trihydrate 570.475mg equivalent to meropenem 500 mg - powder for injection - 500 mg - active: meropenem trihydrate 570.475mg equivalent to meropenem 500 mg excipient: nitrogen sodium carbonate - dbl meropenem for injection is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: · community acquired lower respiratory tract infection · hospital acquired lower respiratory tract infection · complicated urinary tract infection · febrile neutropenia · intra-abdominal and gynaecological (polymicrobial) infections · complicated skin and skin structure infections · meningitis · septicaemia

MEROPENEM HOSPIRA Irland - engelsk - HPRA (Health Products Regulatory Authority)

meropenem hospira

hospira uk limited - meropenem trihydrate - pdr for soln inj/inf - 500 milligram - meropenem

MEROPENEM HOSPIRA Irland - engelsk - HPRA (Health Products Regulatory Authority)

meropenem hospira

hospira uk limited - meropenem trihydrate - pdr for soln inj/inf - 1 grams - meropenem

Meropenem Star Pharmasin 1 g Powder for solution for injection/infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

meropenem star pharmasin 1 g powder for solution for injection/infusion

star pharmasin ltd - meropenem trihydrate - powder for solution for injection/infusion - 1 gram(s) - meropenem

Meropenem Star Pharmasin 500 mg Powder for solution for injection/infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

meropenem star pharmasin 500 mg powder for solution for injection/infusion

star pharmasin ltd - meropenem trihydrate - powder for solution for injection/infusion - 500 milligram(s) - meropenem